Abstract
Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5–10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.
Similar content being viewed by others
References
Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147. https://doi.org/10.1038/nrrheum.2013.174
Sarı I, Birlik M, Kasifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheumatol 1(1):21–33
French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25–31
The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797–807
Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL et al (2008) The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 1 112(5):1794–1803. https://doi.org/10.1182/blood-2008-01-134932
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 15(6):2095–2147 (2187)
Bozkurt Y, Demir A, Erman B, Gül A (2015) Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Comput Math Methods Med 2015:893507. https://doi.org/10.1155/2015/893507
Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146(5):467–478. https://doi.org/10.1111/j.1365-2141.2009.07733.x
Wang DQH, Bonfrate L, de Bari O, Wang TY, Portincasa P (2014) Familial Mediterranean fever: from pathogenesis to treatment. J Genet Syndr Gene Ther 5:248. https://doi.org/10.4172/2157-7412.1000248
Brough D, Rothwell NJ (2007) Caspase-1-dependent processing of pro-interleukin-1 beta is cytosolic and precedes cell death. J Cell Sci 1 120 (Pt 5):772–781
Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586–599
Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95(1):89–97
Bilginer Y, Akpolat T, Ozen S (2011) Renal amyloidosis in children. Pediatr Nephrol 26(8):1215–1227. https://doi.org/10.1007/s00467-011-1797-x
Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheum 21(4):509–514
Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicineresistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545–1546
Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41(2):265–271. https://doi.org/10.1016/j.semarthrit.2010.11.003
Eroglu FK, Beşbaş N, Topaloglu R, Ozen S (2015) Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 35(10):1733–1737. https://doi.org/10.1007/s00296-015-3293-2
Haviv R, Hashkes PJ (2016) Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther 16(11):1425–1434
Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K (2011) The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and long standing destructive arthritis. Ann Rheum Dis 70(7):1347–1348. https://doi.org/10.1136/ard.2010.146878
Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446. https://doi.org/10.1007/s10067-014-2772-2
Sozeri B, Gulez N, Ergin M, Serdaroglu E (2016) The experience of canakinumab in renal amyloidosis secondary to familial Mediterranean fever. Mol Cell Pediatr 3(1):33. https://doi.org/10.1186/s40348-016-0058-2
Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31(4):633–640. https://doi.org/10.1007/s00467-015-3249-5
Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L et al (2015) Renal involvement in secondary amyloidosis of Muckle–Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol 34(7):1311–1316. https://doi.org/10.1007/s10067-013-2481-2
Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885
Ozen S, Kone-Paut I, Gül A (2017) Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum 47(1):115–120. https://doi.org/10.1016/j.semarthrit.2017.03.006
Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282
Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A et al (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) and Turkish FMF study group. Ann Rheum Dis 73(5):897–901. https://doi.org/10.1136/annrheumdis-2013-204719
Cakar N, Yalçinkaya F, Ozkaya N, Tekin M, Akar N, Koçak H et al (2001) Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 19(5 Suppl 24):S63–S67
Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005. https://doi.org/10.1056/nejm198604173141601
Shohat M (2000) In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N (eds) GeneReviews® (internet), 1993–2017. University of Washington, Seattle (updated 15 Dec 2016)
Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E et al (2010) Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37(1):182–189. https://doi.org/10.3899/jrheum.090273
Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690
Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73(2):462–469. https://doi.org/10.1136/annrheumdis-2012-202774
Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29(4 Suppl 67):S87–S90
Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 29(2):209–210. https://doi.org/10.1007/s10067-009-1279-8
Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25(4):621–624. https://doi.org/10.3109/14397595.2014.987437
Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 13(5):393–404. https://doi.org/10.1080/1744666X.2017.1313116
Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L et al (2014) Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study (Hoboken, NJ). Arthritis Rheumatol (Hoboken NJ) 66(11):3241–3243. https://doi.org/10.1002/art.38777
Ozkan S, Atas B (2017) Canakinumab treatment in four children with colchicine resistant familial mediterranean fever. J Pak Med Assoc 67(6):945–947
Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 17:243. https://doi.org/10.1186/s13075-015-0765-4
Salehzadeh F, Yasrebi O, Hosseini Khotbesara M, Hosseini Khotbesara M (2014) Idiopathic uveitis and familial Mediterranean fever: is there any relationship? Autoimmune Dis 2014:238931. https://doi.org/10.1155/2014/238931
Berestizschevsky S, Weinberger D, Avisar I, Avisar R. Episcleritis associated with familial Mediterranean fever. Isr Med Assoc J 10(4):318–319
Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2015) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 34(7):1293–1301. https://doi.org/10.1007/s10067-013-2443-8
Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591. https://doi.org/10.1136/annrheumdis-2012-201383
Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197. https://doi.org/10.1007/s10067-016-3506-4
Brambilla A, Caputo R, Cimaz R, Simonini G (2016) Canakinumab for childhood sightthreatening refractory uveitis: a case series. J Rheumatol 43(7):1445–1447. https://doi.org/10.3899/jrheum.160064
Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R et al (2015) Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study. J Ophthalmic Inflamm Infect 5(1):34. https://doi.org/10.1186/s12348-015-0065-9
Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. ArthritisRheum 65(2):513–518. https://doi.org/10.1002/art.37776
Funding
No funding.
Author information
Authors and Affiliations
Contributions
Study conception and design: FY and OA. Acquisition of data: contribution of all authors. Analysis and interpretation of data: FY and SGÖ. Drafting of manuscript: FY and MB. Critical revision: contribution of all authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Yazılıtaş, F., Aydoğ, Ö., Özlü, S.G. et al. Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int 38, 879–885 (2018). https://doi.org/10.1007/s00296-018-3993-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-018-3993-5